Skip to content
sellModerate cluster of 2

Southpoint Capital Advisors LP sold $2.0M of FENC

owner at FENNEC PHARMACEUTICALS INC.. 246,018 shares at an average of $8.27, traded Nov 14, 2025, filed Nov 17, 2025.

Warning score
45
Value
$2.0M
246,018 shares
Holdings after
3,764,082
-6% from before
From 52-week low
+97%
low $3.99, close $7.86
From 52-week high
-20%
high $9.88, as of Nov 14, 2025

Score components

  • Role
    10% owner
    +12
  • Trade size
    $2.0M at market
    +25
  • Share of holdings sold
    Sold 6.1% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -13.8%, 3m -3.8%, 6m +9.7%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

FENCOct 12, 2026 · close 10.72
Since filing Nov 17, 2025: +22.5%SPY +18.1% · excess +4.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001012975-25-000793, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 14, 2025SOpen-market sale
Common Stockindirect: See Footnote
-160,100$8.00$1.3M3,850,000Nov 17, 2025
Nov 17, 2025SOpen-market sale
Common Stockindirect: See Footnote
-85,918$8.79$755k3,764,082Nov 17, 2025

Related signals

Other insiders at FENNEC PHARMACEUTICALS INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
19Weak
FENCsell 210b5-1
FENNEC PHARMACEUTICALS INC.
Marco Maria Brughera
director
$160k
15,545 shares
-100%
13Weak
FENCsell 410b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
CHIEF EXECUTIVE OFFICER
$121k
10,000 shares
-7%
61Notable
FENCsell 3
FENNEC PHARMACEUTICALS INC.
Pierre Sargis Sayad
Chief Medical Officer
$146k
12,000 shares
-56%
35Weak
FENCsell 310b5-1
FENNEC PHARMACEUTICALS INC.
Robert Andrade
CHIEF FINANCIAL OFFICER
$884k
75,000 shares
-26%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
CHIEF EXECUTIVE OFFICER
$96k
10,000 shares
-7%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
CHIEF EXECUTIVE OFFICER
$100k
9,599 shares
-6%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
CHIEF EXECUTIVE OFFICER
$94k
9,747 shares
-7%
0Weak
FENCsell 210b5-1
FENNEC PHARMACEUTICALS INC.
Chris A Rallis
director
$59k
8,346 shares
-12%
0Weak
FENCsell 210b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
CHIEF EXECUTIVE OFFICER
$70k
10,781 shares
-8%
0Weak
FENCsell10b5-1
FENNEC PHARMACEUTICALS INC.
Rosty Raykov
CHIEF EXECUTIVE OFFICER
$69k
10,946 shares
-9%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Southpoint Capital Advisors LP sold $2.0M of FENC | InsiderTell